Source: Investing.com ↗

Zipalertinib trial meets primary endpoint in lung cancer study

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

BTC/USDT

$77,293.08

+1.69%

ETH/USDT

$2,454.29

+2.73%

USDC/USDT

$1.00

-0.01%

XRP/USDT

$1.48

+0.94%

SOL/USDT

$94.07

+1.66%